HC Wainwright reiterated their buy rating on shares of Aligos Therapeutics (NASDAQ:ALGS – Free Report) in a research report sent to investors on Friday, Benzinga reports. They currently have a $75.00 price target on the stock.
Aligos Therapeutics Price Performance
ALGS stock opened at $8.10 on Friday. The company’s 50-day moving average is $13.09 and its 200-day moving average is $16.08. Aligos Therapeutics has a 1 year low of $7.80 and a 1 year high of $30.00. The stock has a market capitalization of $632.69 million, a PE ratio of -6.33 and a beta of 2.18.
Aligos Therapeutics (NASDAQ:ALGS – Get Free Report) last released its quarterly earnings data on Tuesday, August 6th. The company reported $0.75 EPS for the quarter, beating the consensus estimate of ($4.00) by $4.75. Aligos Therapeutics had a negative return on equity of 110.59% and a negative net margin of 1,100.48%. The firm had revenue of $1.06 million during the quarter. During the same quarter in the prior year, the firm earned ($10.75) EPS. On average, analysts anticipate that Aligos Therapeutics will post -8.15 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Aligos Therapeutics
About Aligos Therapeutics
Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).
Featured Articles
- Five stocks we like better than Aligos Therapeutics
- Why Invest in High-Yield Dividend Stocks?
- The Average 401k Balance by Age Explained
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- 3 Uranium Stocks To Gain as Microsoft Goes Nuclear to Power AI
- Investing In Automotive Stocks
- Biotech Boom Ahead? Key Stocks and ETFs to Watch Now
Receive News & Ratings for Aligos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aligos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.